Guangzhou Innogen Pharmaceutical Group

Guangzhou Innogen Pharmaceutical Group is a clinical-stage biopharmaceutical company headquartered in Guangzhou, China, specializing in the development of innovative treatments for metabolic diseases, with a primary focus on diabetes and obesity. The company's portfolio features a robust pipeline of insulin analogues and next-generation incretin-based therapies, including insulin degludec, insulin aspart, and GLP-1/GIP receptor agonists. Innogen operates integrated research, development, and manufacturing facilities in Guangzhou and Suzhou to support its goal of providing high-quality, affordable metabolic medicines. Its lead programs, such as the insulin degludec/aspart co-formulation INS068, are currently in late-stage clinical development, aiming to address the growing global burden of endocrine disorders. The company is backed by prominent Chinese venture capital firms and maintains a strong focus on the domestic market while exploring international opportunities.